ArticleJournal of clinical pharmacology2026
Comments to the Article Wu Y, Völler S, Goulooze SC, et al. A Novel Maturation Equation for Hepatic Clearance Across Preterm, Term Neonates, Children, and Adults: Application to Paracetamol and Its Metabolite. J Clin Pharmacol. 2025;65(12):1829-1843. doi: 10.1002/jcph.70080. PMID: 40910464; PMCID: PMC12649303.
Article in Journal of clinical pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
- Comment on
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A recent article in this journal by Wu et al presented a comprehensive model for the maturation of paracetamol clearance from birth to adulthood using pooled plasma and urinary data of the parent drug and its metabolites from 298 subjects. The modeling showed that the oxidative bioactivation to hepatotoxic metabolite N-acetyl-p-benzoquinone imine (NAPQI) is generally around 10% of the total clearance. We would like to comment on the authors' discussion on the formation of NAPQI, which highlights once again the main role of CYP2E1 in the oxidative bioactivation metabolism of paracetamol. CYP2E1 was demonstrated as a primary catalyst in the bioactivation of paracetamol, referring only to the paper of Johnsrud et al, that describes only the developmental phase of CYP2E1 in man.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.